Areca catechu L. procyanidins alleviate pulmonary fibrosis by suppressing the TGF-β/Smad/ERK cascade: Validation of a traditional herbal medicine.
Areca nut procyanidins may reduce collagen deposition and improve lung histopathology in pulmonary fibrosis models, but human relevance is unclear.
Where it sits
this study against the rest of the ghrp-6 corpusSummary and findings
This study investigated the effects of areca nut procyanidins (ANP) on pulmonary fibrosis (PF) in rat models and fibroblast cells. ANP was administered at doses of 1, 5, and 15 mg/kg for 28 days. The study aimed to elucidate the mechanisms underlying the anti-fibrotic activity of ANP.
Abstract
<h4>Ethnopharmacological relevance</h4>Areca nut has long been prescribed in Traditional Chinese Medicine for respiratory disorders resembling pulmonary fibrosis (PF). Its classical effects of resolving phlegm and dissipating chest stagnation, documented in Shennong Bencao Jing, align closely with PF's hallmark pathologies of interstitial scarring and excessive collagen accumulation, yet the mechanistic basis for its anti-fibrotic activity remains unelucidated.<h4>Aim of the study</h4>This study validated the anti-PF efficacy of areca nut procyanidins (ANP) and elucidated their multi-target mechanisms.<h4>Materials and methods</h4>A multi-faceted approach integrating network pharmacology, molecular docking, and in vivo/vitro experiments was employed. Rat PF models induced by bleomycin were treated with ANP (1, 5, 15 mg/kg) for 28 days. LPS-stimulated 3T6 fibroblasts were used to evaluate cellular mechanisms.<h4>Results</h4>Network pharmacology predicted 72 common targets, with enrichment in the TGF-β and MAPK pathways. Molecular docking confirmed strong binding affinity of ANP to TGF-β1 (-8.8 kcal/mol) and Smad3 (-6.8 kcal/mol). In vivo, medium- and high-dose ANP significantly ameliorated lung histopathology, reduced collagen deposition (HYP), and restored antioxidant biomarkers (T-AOC, MPO, GSH). Mechanistically, ANP concurrently suppressed the TGF-β/Smad/ERK signaling cascade, characterized by the downregulation of TGF-β1, p-Smad3/4, and p-ERK, alongside the restoration of the inhibitory Smad7. In vitro, ANP inhibited fibroblast migration, inflammation (IL-1β, TNF-α), and extracellular matrix production.<h4>Conclusion</h4>By multi-target inhibition of the TGF-β/Smad/ERK cascade, ANP ameliorates PF, consistent with areca nut's traditional phlegm-resolving and nodule-dissipating properties. Compared with pirfenidone, ANP exhibits superior safety and multi-pathway activity, rendering it a promising botanical therapeutic agent for PF.
Background
This paper addresses the potential anti-fibrotic properties of areca nut procyanidins (ANP) in the context of pulmonary fibrosis (PF). Previous studies have indicated that traditional herbal medicines may offer therapeutic benefits for respiratory disorders, yet the specific mechanisms of action for ANP remain unclear. Understanding these mechanisms is crucial for validating the traditional use of areca nut in treating PF.
Methods
The study employed a multi-faceted approach, integrating network pharmacology, molecular docking, and both in vivo and in vitro experiments. Rat models of PF were induced using bleomycin and treated with ANP at doses of 1, 5, and 15 mg/kg for 28 days. The primary outcome measures included lung histopathology, collagen deposition, and various antioxidant biomarkers.
Results
The primary endpoint indicated that ANP at medium and high doses significantly ameliorated lung histopathology and reduced collagen deposition, although specific numeric values for these findings were not reported. Network pharmacology identified 72 common targets enriched in the TGF-β and MAPK pathways. In vitro findings demonstrated that ANP inhibited fibroblast migration and inflammatory cytokines.
Interpretation
While the study presents findings that suggest ANP may have beneficial effects on PF, the clinical significance of these results remains uncertain given the reliance on animal models and in vitro data. The effect sizes reported may not translate to meaningful clinical outcomes in humans. Additionally, the study lacks details on sample sizes and potential confounding factors that could influence the results.
Key findings
- ANP treatment at 5 mg/kg and 15 mg/kg significantly reduced collagen deposition (HYP), n=Not reported in abstract.
- Molecular docking showed ANP had a binding affinity of -8.8 kcal/mol to TGF-β1 and -6.8 kcal/mol to Smad3.
- ANP significantly downregulated TGF-β1, p-Smad3/4, and p-ERK, alongside restoration of Smad7, n=Not reported in abstract.
- In vitro, ANP inhibited IL-1β and TNF-α production, n=Not reported in abstract.
Limitations
- small n=Not reported in abstract
- rodent only, no human data
- in vitro findings may not translate to clinical settings
- short follow-up duration of 28 days